Patented Medicine Prices Review Board Schedules a Pre-Hearing Conference in the Matter of Alexion Pharmaceuticals Inc. and the Price of the Medicine Soliris
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwired) -- 06/18/15 -- Patented Medicine Prices Review Board
The Patented Medicine Prices Review Board (PMPRB) will hold a public pre-hearing conference in the matter of the price of the patented medicine Soliris and Alexion Pharmaceuticals Inc., the pharmaceutical company that exercises patent rights for Soliris and sells the medicine in Canada. The pre-hearing conference will take place from 9:30 a.m. to 5:00 p.m. (EST) on Monday, June 22; Tuesday, June 23; and Wednesday, June 24, 2015 at the following location:
The purpose of the pre-hearing conference is to allow parties to identify or circumscribe the issues related to the hearing and resolve any other issues that may facilitate the conduct of the hearing.
Soliris is the first and only treatment for patients with Paroxysmal Nocturnal Hemoglobinuria-a rare and life-threatening blood disorder characterized by excessive destruction of red blood cells-and Atypical Hemolytic Uremic Syndrome, a rare and life-threatening genetic disorder characterized by blood clots in small vessels.
Quick Facts
Related Products
Additional Links
(Patented Medicine Prices Review Board)
(Patented Medicine Prices Review Board)
Contacts:
Sofie McCoy-Astell
Manager, Communications
Patented Medicine Prices Review Board
613-960-9728
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 18.06.2015 - 19:00 Uhr
Sprache: Deutsch
News-ID 401613
Anzahl Zeichen: 0
contact information:
Town:
OTTAWA, ONTARIO
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 229 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Patented Medicine Prices Review Board Schedules a Pre-Hearing Conference in the Matter of Alexion Pharmaceuticals Inc. and the Price of the Medicine Soliris"
steht unter der journalistisch-redaktionellen Verantwortung von
Patented Medicine Prices Review Board (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
